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Background: The J-Land 3S trial demonstrated that landiolol is effective and tolerated for treating sepsis-
related tachyarrhythmias. Patient characteristics (e.g. baseline heart rate [HR], type of tachyarrhythmia, and
concomitant disorders) may impact the outcomes of landiolol therapy. We performed subanalyses of J-Land
3S to evaluate the impact of patient characteristics on the efficacy and safety of landiolol for treating sepsis-
related tachyarrhythmia.
Methods: Patients (20 years old; N = 151) hospitalised with sepsis at 54 participating hospitals in Japan with
HR 100 beats/min for 10 min accompanied by diagnosis of tachyarrhythmia were randomised 1:1 to con-
ventional sepsis therapy alone (control group) or conventional sepsis therapy plus landiolol (landiolol group).
The efficacy and safety of landiolol were assessed in prespecified analyses of patients divided into subgroups
by baseline characteristics and in post hoc, multivariate analyses with adjustment for age and HR at baseline.
Findings: The percentage of patients with HR of 6094 beats/min at 24 h after randomisation (primary end-
point) was greater in the landiolol group in most subgroups in univariate unadjusted analyses and in multi-
variate logistic regression. The incidence of new-onset arrhythmia by 168 h and mortality by 28 days were
also lower in the landiolol group in most subgroups in univariate and multivariate Cox proportional hazards
models. No subgroups showed a markedly higher incidence of adverse events in univariate or multivariate
logistic regression analyses.
Interpretation: These results of the J-Land 3S study suggest that the efficacy and safety of landiolol are gener-
ally unaffected by key patient characteristics.
Funding: Ono Pharmaceutical Co., Ltd.
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Sepsis is defined as life-threatening organ dysfunction caused by a
dysregulated host response to infection. Sepsis is known to induce
sympathetic hyperactivity and exacerbate the inflammatory responseaccompanying infection, resulting in further organ damage and dys-
function [14]. Although acute renal injury and acute respiratory dis-
tress syndrome (ARDS) are the predominant complications, many
patients may experience septic shock due to excessive vasodilation
and cardiac dysfunction [57]. A decrease in tissue circulation often
causes a rise in lactic acid levels and metabolic acidosis.
Tachyarrhythmias (atrial fibrillation, atrial flutter, and sinus
tachycardia) often develop in patients with sepsis due to excessive
Research in context
Evidence before this study
Sepsis is a life-threatening organ dysfunction caused by an
inappropriate response to infection, and is frequently associ-
ated with cardiovascular disorders, such as tachycardia. Reduc-
ing the heart rate (HR) to <95 beats/min soon after the onset of
tachycardia can improve the prognosis of patients with sepsis-
related tachyarrhythmias. Landiolol is an ultra-short-acting
b1-selective antagonist that is already available for the man-
agement of atrial fibrillation and atrial flutter in critically ill
patients, including those with cardiac dysfunction or renal fail-
ure. Preliminary evidence also suggested that landiolol may be
effective for the management of sepsis-related tachyarrhyth-
mias, a possibility that was evaluated in the phase II/III J-Land
3S study. The study demonstrated that landiolol resulted in sig-
nificantly more patients with sepsis-related tachyarrhythmia
achieving a heart rate of 6094 beats/min at 24 h and signifi-
cantly reduced the incidence of new-onset arrhythmia. Landio-
lol was also well tolerated in these patients. The prognosis of
sepsis-related tachyarrhythmias may also be influenced by
patient characteristics or other clinical events, like acute kidney
injury. Therefore, evidence is needed on the efficacy and safety
of landiolol in patients with such factors.
Added value of this study
Here, we performed subanalyses of the J-Land 3S study in order
to evaluate the efficacy and safety of landiolol in patients
divided into subgroups according to a variety of baseline clini-
cal characteristics associated with poor prognosis of sepsis-
related tachyarrhythmias. The results of prespecified univariate
analyses as well as post hoc multivariate analyses with adjust-
ment for age and heart rate at baseline indicate that landiolol
demonstrated promising efficacy (measured in terms of the
percentage of patients with HR of 6094 beats/min at 24 h, per-
centage of patients with new-onset arrhythmia, and mortality
by 28 days) in most subgroups of patients relative to the control
group. In terms of safety, we observed no subgroups of landio-
lol-treated patients with a profound increase in the incidence
of adverse events relative to the control group based on univar-
iate and multivariate analyses.
Implications of all the available evidence
Results of the J-Land 3S study, as reported here and in the prior
report, provide valuable evidence supporting the efficacy and
safety of landiolol in patients with sepsis-related tachyarrhyth-
mias. The present results also mimic the subanalyses performed
in an earlier study (J-Land) in which patients with atrial fibrilla-
tion or atrial flutter complicated with left ventricular dysfunc-
tion were randomised to landiolol or digoxin. Those results,
and the present findings, suggest that the efficacy and safety of
landiolol is generally unaffected by baseline characteristics,
supporting its use in a wide range of patients who develop sep-
sis-related tachyarrhythmias, for whom the prognosis is other-
wise quite poor.
2 N. Matsuda et al. / EClinicalMedicine 28 (2020) 100571sympathetic hyperactivity and elevated levels of inflammatory cyto-
kines. The onset of tachycardia or atrial fibrillation is an independent
prognostic factor in patients with sepsis or other serious disorders
[815]. Tachyarrhythmias in critically ill patients are typically treated
with b-blockers, calcium channel blockers, digitalis preparations,
sodium channel blockers, or potassium channel blockers. However,these drugs may be contraindicated or of limited benefit in patients
with cardiac dysfunction, renal failure, or other comorbidities (car-
diogenic shock or acidosis, for example). Furthermore, the pharmaco-
kinetic characteristics of these drugs may make them difficult to use
in critically ill patients [16,17]. Accordingly, alternative drugs that
can be used over a wide spectrum of conditions, regardless of comor-
bidities like cardiac dysfunction, renal failure, or acidosis, are needed
for the treatment of sepsis-related tachyarrhythmias.
Landiolol is an ultra-short-acting b1-selective antagonist that is
already available for the management of atrial fibrillation and atrial
flutter in critically ill patients, including those with cardiac dysfunc-
tion or renal failure [1820]. It is also used to treat intraoperative/
postoperative tachyarrhythmias and ventricular fibrillation or ven-
tricular tachycardia [18,21,22]. Preliminary evidence also revealed
the potential use of landiolol for the management of sepsis-related
tachyarrhythmias [2325], a possibility that was evaluated in the
J-Land 3S study [26]. This was a multicentre, open-label, phase II/III
study performed in Japan in which patients who developed sepsis-
related tachyarrhythmias (atrial fibrillation, atrial flutter, and sinus
tachycardia) were randomised to receive conventional sepsis therapy
with or without landiolol. The study showed that administration of
landiolol was superior to conventional sepsis therapy in terms of
lowering heart rate (HR) within 24 h after randomisation, with a
lower rate of new-onset arrhythmia by 168 h after randomisation.
The study showed that landiolol was also well tolerated in patients
with sepsis-related tachyarrhythmias.
The type of tachyarrhythmia, the presence of other complications
(e.g. acute kidney injury, ARDS), and other clinical characteristics
may impact on the outcomes of sepsis-related tachyarrhythmia.
Therefore, we performed prespecified and post hoc subanalyses of
the J-Land 3S study in order to evaluate the efficacy and safety of
landiolol in patients divided into subgroups according to these clini-
cal characteristics.
2. Methods
The design of the J-Land 3S study is published in full elsewhere,
together with its study protocol [26]. This study adhered to the Decla-
ration of Helsinki and Good Clinical Practice, and was approved by
the ethical review boards at all participating sites. This study was reg-
istered on the Japan Pharmaceutical Information Center - Clinical Tri-
als Information database (JapicCTI-173767).
2.1. Patients
The inclusion and exclusion criteria are listed in more detail in our
previous report [26]. Patients (20 years old) hospitalised at one of 54
hospitals in Japan who developed sepsis according to the Japanese
Clinical Practice Guidelines for the Management of Sepsis and Septic
Shock 2016 (J-SSCG 2016) [27] and the Third International Consensus
Definitions for Sepsis and Septic Shock (Sepsis-3) [4] were eligible if
their HR was maintained at 100 beats/min for 10 min without a
change in catecholamine dose and was accompanied by a diagnosis of
atrial fibrillation, atrial flutter, and/or sinus tachycardia. Only patients
whose symptoms and signs could be confirmed within 24 h before
randomisation and within 72 h after entering an intensive care unit
could be registered. The attending physicians were required to stabi-
lise the patient’s hemodynamic status before randomisation. Written,
informed consent was obtained from the patient or next of kin.
Patients who subsequently developed a tachyarrhythmia and met the
eligibility criteria were registered and eligible for randomisation [26].
2.2. Study design
Following enrolment, patients were randomised 1:1 to receive
either conventional sepsis therapy alone (control group) or
Table 1
Patient characteristics.
Overall Landiolol group Control group
N = 151 N = 76 N = 75
Sex
Male 90 (596) 52 (684) 38 (507)
Female 61 (404) 24 (316) 37 (493)
Age (years)
N. Matsuda et al. / EClinicalMedicine 28 (2020) 100571 3conventional sepsis therapy plus landiolol (landiolol group). Ran-
domisation was stratified by HR at the time of randomisation (100
to <120 beats/min or 120 beats/min) and age (<70 years or 70
years). Patients in both groups were to be treated in accordance with
the J-SSCG 2016 recommendations [27], including respiratory and
fluid resuscitation, antimicrobials, and catecholamines, as deemed
necessary. Prohibited and approved concomitant drugs are listed in
the prior report [26].<70 73 (483) 37 (487) 36 (480)
70 78 (517) 39 (513) 39 (520)
Mean (SD) 671 (145) 678 (138) 664 (152)
Heart rate (beats/min)
<120 89 (601) 43 (589) 46 (613)
120 59 (399) 30 (411) 29 (387)
Missing 3 3 0
Mean (SD) 1175 (140) 1174 (147) 1176 (134)
Diagnosis
Atrial fibrillation 29 (192) 17 (224) 12 (160)
Sinus tachycardia 121 (801) 58 (763) 63 (840)
Atrial fibrillation and atrial
flutter
1 (07) 1 (13) 0 (00)
Left ventricular ejection fraction (%)
<50 53 (353) 28 (373) 25 (333)
50 97 (647) 47 (627) 50 (667)
Missing 1 1 0
Mean (SD) 5513 (1543) 5401 (1447) 5624 (1635)2.3. Landiolol dosing
The administration of landiolol was mandatory for the first 96 h,
starting within 2 h after randomisation. Its starting dose was 1 mg/
kg/min (intravenous) and could be increased by 1 mg/kg/min gener-
ally every 1520 min until the HR had decreased to <95 beats/min.
Administration of landiolol was optional between 96 and 168 h, dur-
ing which time the dose could be increased/decreased as appropriate
by 1 mg/kg/min. The maximum permitted dose of landiolol was
20 mg/kg/min. After 96 h, the patient could be switched to oral or
percutaneous b-blockers. The landiolol dose was to be reduced or
discontinued if systolic blood pressure decreased by 20% from ran-
domisation or if HR decreased to <60 beats/min.Systolic blood pressure (mmHg)
<120 84 (556) 40 (526) 44 (587)
120 67 (444) 36 (474) 31 (413)
Mean (SD) 1193 (222) 1211 (229) 1174 (214)
Infection site
Respiratory organ 45 (298) 22 (289) 23 (307)
Other organ 106 (702) 54 (711) 52 (693)
Comorbid septic shock
Yes 137 (907) 69 (908) 68 (907)
No 14 (93) 7 (92) 7 (93)
Comorbid acute kidney injury
Yes 98 (649) 44 (579) 54 (720)
No 53 (351) 32 (421) 21 (280)
Comorbid ARDS
Yes 31 (205) 19 (250) 12 (160)
No 120 (795) 57 (750) 63 (840)
pH
<735 47 (311) 28 (368) 19 (253)
735 104 (689) 48 (632) 56 (747)
Mean (SD) 7383 (0091) 7370 (0100) 7395 (0079)
SOFA score (total)
<10 66 (437) 33 (434) 33 (440)
10 85 (563) 43 (566) 42 (560)
Mean (SD) 101 (30) 100 (31) 101 (30)
APACHE II score
<25 98 (649) 51 (671) 47 (627)
25 53 (351) 25 (329) 28 (373)
Mean (SD) 227 (87) 231 (89) 222 (86)
eGFR (mL/min/173 m2)
<30 65 (430) 27 (355) 38 (507)
30 86 (570) 49 (645) 37 (493)
Mean (SD) 438 (311) 489 (324) 386 (290)
pH <74 and HCO3 <24 mmol/L
Yes 63 (417) 32 (421) 31 (413)
No 88 (583) 44 (579) 44 (587)
pH <74 and PaCO2 >45 mmHg
Yes 21 (139) 17 (224) 4 (53)
No 130 (861) 59 (776) 71 (947)
Values are n (%) or mean (SD). Analyses were done on an as-assigned basis (safety
analysis set).
APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respira-
tory distress syndrome; beats/min = beats per minute; eGFR = estimated glomerular
filtration rate; SD = standard deviation; SOFA = Sequential Organ Failure Assessment.2.4. Endpoints and analyses
The endpoints are listed in more detail in the prior report [26]. For
the purpose of the present analyses, we focused on the primary end-
point (HR of 6094 beats/min at 24 h after randomisation) and the
following secondary/safety endpoints: new-onset arrhythmia by
168 h after randomisation, mortality by 28 days after randomisation,
and adverse events by 168 h after randomisation.
Adverse events were defined as any undesirable or unintended
sign (including abnormal laboratory values), symptom, or disease
that occurred after randomisation, regardless of their causal relation-
ship to the study. Exacerbation of an underlying disease or associated
symptoms of the underlying disease, or complications that are medi-
cally judged to have gone beyond the extent of the natural course
were also regarded as adverse events.
The four endpoints were compared between the landiolol and
the control groups for subgroups of patients divided by baseline
characteristics (see Table 1) that were considered likely to influ-
ence or confound the efficacy and safety outcomes. These analy-
ses were prespecified in the statistical analysis plan and were
conducted a priori.
In the prespecified univariate analyses of patient subgroups, the
percentage difference (landiolol minus control) with 95% Newcombe
confidence intervals (CI) was determined for the percentages of
patients with HR of 6094 beats/min at 24 h after randomisation and
the percentages of patients with adverse events by 168 h without
adjustment for covariates. Unadjusted hazard ratios were determined
using the Cox proportional hazards model (with 95% CI) for new-
onset arrhythmia by 168 h after randomisation and mortality by
28 days after randomisation. As post hoc analyses, we used multivari-
ate logistic regression to compare for the percentages of patients with
HR of 6094 beats/min at 24 h after randomisation and the percen-
tages of patients with adverse events by 168 h, and the multivariate
Cox proportional hazards model for new-onset arrhythmia by 168 h
after randomisation and mortality by 28 days after randomisation
among the prespecified subgroups of patients. The post hoc multivar-
iate analyses were adjusted for age and HR at baseline, which were
used as allocation factors for randomising patients to the study
groups.
Landiolol dosing characteristics (maximum dose within 24 h, dose
at 24 h, average dose during the study, maximum dose during the
study, and total dosing time) were determined in each subgroup in apost hoc manner. Landiolol doses are reported as the mean (standard
deviation).
As the analyses were conducted in an exploratory manner, no
p-values were calculated. All analyses were performed using SAS ver-
sion 9.3 (SAS Institute, Cary, NC, USA).
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Employees of Ono Pharmaceutical Co., Ltd. contributed to study
design, data analysis, and writing the manuscript. The corresponding
author had full access to the data and was responsible for the decision
to submit the manuscript.
3. Results
3.1. Patients
One hundred and fifty-one patients were randomised, of
which 76 were allocated to the landiolol group and 75 to the con-
trol group (Fig. 1). The efficacy analysis set involved 75 patients
in each group and the safety analysis set comprised 77 patients
in the landiolol group and 74 in the control group. The baseline
characteristics of patients are reported in Table 1. Both groups
were generally well matched, except for the proportion of males,
presence of comorbid ARDS, pH <735, and the combination of
pH <74 and PaCO2 >45 mmHg, which were more frequent in
the landiolol group, and the presence of comorbid acute kidney
injury and eGFR <30 mL/min/173 m2, which were more frequent
in the control group.
3.2. HR control
As previously reported, the percentage of patients with HR
6094 beats/min at 24 h was higher in the landiolol group than
in the control group (547% [41/75] vs. 333% [25/75]) with a per-
centage difference of 213 (95% CI 54 to 358) in the univariate
analysis (Fig. 2). This difference was also maintained in the multi-
variate analysis with adjustment for age and HR at baseline (oddsFig. 1. Trial profile (reprinted with permission from Kakihana et al. Lancet Respiratory Medic
*Multiple reasons may apply. yOne patient assigned to the control group was incorrectly
and in the landiolol group for the safety analysis. zOne patient assigned to the landiolol gro
excluded from the efficacy analysis but was included in the safety analysis.ratio 280, 95% CI 137 to 569; Fig. S1). In univariate, unadjusted
analyses (Fig. 2), the percentage of patients with HR
6094 beats/min at 24 h was greater in the landiolol group in
most subgroups of patients, and the numerically largest differ-
ence (landiololcontrol) was found in patients without septic
shock (percentage difference 714; 95% CI 191 to 880). Similar
findings were also apparent in the multivariate analyses with
adjustment for age and HR at baseline, and the largest difference
(landiololcontrol) was found in patients with respiratory organ
infection (odds ratio 1651; 95% CI 206 to 13209) (Fig. S1). How-
ever, the efficacy of landiolol was attenuated in some subgroups,
including patients with a baseline HR of 120 beats/min (unad-
justed percentage difference 34; 95% CI 187 to 251; Fig. 2;
adjusted odds ratio 136; 95% CI 040 to 1036; Fig. S1) and
patients with a diagnosis of atrial fibrillation (unadjusted percent-
age difference 05; 95% CI 333 to 314; Fig. 2; adjusted odds
ratio 125; 95% CI 025 to 622; Fig. S1). In the control group, two
of the seven patients with a baseline HR of 120 beats/min, and
three of the five patients with atrial fibrillation were adminis-
tered prohibited concomitant b-blockers as rescue therapy within
24 h of randomisation. None of the other baseline characteristics
had a marked influence on the HR reduction with landiolol.
3.3. New-onset arrhythmia
New-onset arrhythmia occurred by 168 h in 93% (7/75) of
patients in the landiolol group versus 253% (19/75) of patients in
the control group, with an unadjusted hazard ratio of 0357 (95%
CI 0150 to 0849) in favour of landiolol (Fig. 3). This difference
was maintained after adjustment for age and HR at baseline with
a hazard ratio of 0351 (95% CI 0147 to 0835; Fig. S2). The unad-
justed and adjusted hazard ratios for the incidence of new-onsetine 2020;8:863872).
given landiolol. This patient was included in the control group for the efficacy analysis
up did not meet the inclusion criteria but was administered landiolol. This patient was
Fig. 2. Subgroup analysis of the percentage of patients whose heart rate (HR) was adjusted to 6094 beats/min at 24 h after randomisation.
The size of the markers represents the number of patients included in the subgroup. Results of the multivariate analysis with adjustment for age and HR at baseline are shown in
Fig. S1.
APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; beats/min = beats per minute; CI = confidence interval;
eGFR = estimated glomerular filtration rate; SOFA = Sequential Organ Failure Assessment.
N. Matsuda et al. / EClinicalMedicine 28 (2020) 100571 5arrhythmia generally favoured landiolol in most subgroups,
except in patients with systolic blood pressure of 120 mmHg at
baseline (unadjusted hazard ratio 0964; 95% CI 0279 to 3331;
Fig. 3; adjusted hazard ratio 0997; 95% CI 0276 to 3607;
Fig. S2).3.4. Mortality by 28 days
Nine of 75 patients (120%) in the landiolol group and 15 of 75 in
the control group (200%) died by 28 days of randomisation with an
unadjusted hazard ratio of 0599 (95% CI 0262 to 1370; Fig. 4) and
Fig. 3. Subgroup analysis of the percentage of patients who developed new arrhythmias by 168 h after randomisation.
The size of the markers represents the number of patients included in the subgroup. Hazard ratios are plotted on a log-scale. Results of the multivariate analysis with adjustment
for age and heart rate at baseline are shown in Fig. S2.
APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; beats/min = beats per minute; CI = confidence interval;
eGFR = estimated glomerular filtration rate; NC = upper limit not calculable; SOFA = Sequential Organ Failure Assessment.
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which tended to favour landiolol. The unadjusted and adjusted
hazard ratios tended to favour landiolol in most subgroups of
patients, although the 95% CIs crossed 1 for most comparisons
(Figs. 4 and S3). This tendency was relatively strong amongpatients with a Sequential Organ Failure Assessment (SOFA) score
of <10 (unadjusted and adjusted hazard ratio 0000) or those
with a respiratory organ infection (unadjusted hazard ratio 0259;
95% CI 0071 to 0943, adjusted hazard ratio 0188; 95% CI 0040
to 0893).
Fig. 4. Subgroup analysis of mortality by 28 days after randomisation.
The size of the markers represents the number of patients included in the subgroup. Hazard ratios are plotted on a log-scale. Results of the multivariate analysis with adjustment
for age and heart rate at baseline are shown in Fig. S3.
APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; beats/min = beats per minute; CI = confidence interval;
eGFR = estimated glomerular filtration rate; NC = upper limit not calculable; SOFA = Sequential Organ Failure Assessment.
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Adverse events (of any grade or seriousness) occurred by 168 h in
636% (49/77) of patients in the landiolol group versus 595% (44/74)
in the control group, with an unadjusted percentage difference of 42(95% CI 111 to 192; Fig. 5) and adjusted odds ratio of 120 (95% CI
062 to 232; Fig. S4). Although the percentage of patients with
adverse events was slightly greater with landiolol in most subgroups
of patients, no subgroup showed a markedly higher incidence of
adverse events in the unadjusted analyses (Fig. 5) or after adjustment
Fig. 5. Subgroup analysis of overall adverse events.
The size of the markers represents the number of patients included in the subgroup. Results of the multivariate analysis with adjustment for age and heart rate at baseline are
shown in Fig. S4.
APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; beats/min = beats per minute; CI = confidence interval;
eGFR = estimated glomerular filtration rate; SOFA = Sequential Organ Failure Assessment.
8 N. Matsuda et al. / EClinicalMedicine 28 (2020) 100571for age and HR at baseline (Fig. S4). However, the percentage of
patients with an adverse event was lower in the subgroup of patients
with ARDS (526% [10/19] vs. 917% [11/12]; unadjusted percentage
difference 390; 95% CI 611 to 54; adjusted odds ratio 009;
95% CI 001 to 092).3.6. Landiolol dosing
The landiolol dose was analysed in patients stratified according to
whether or not they experienced any of the four endpoints listed
above, and in each of the patient subgroups. In all 76 patients who
N. Matsuda et al. / EClinicalMedicine 28 (2020) 100571 9were allocated to landiolol, the maximum dose within 24 h was 611
(573) mg/kg/min, the dose at 24 h was 577 (557) mg/kg/min, the
average dose during the study was 415 (435) mg/kg/min, and the
maximum dose during the study was 696 (626) mg/kg/min. The
mean duration of administration was 9449 (4349) h (Tables S1 and
S2). When patients were stratified by the efficacy variables, we found
that patients who achieved the primary endpoint, patients who did
not experience new-onset arrhythmia, and patients who were alive
at 28 days after randomisation appeared to have lower doses of land-
iolol than the other subgroups (Table S1). Landiolol doses also
appeared to be lower in patients with adverse events than in patients
without adverse events. When landiolol dosing was analysed accord-
ing to patient subgroups (Table S2), there appeared to be differences
in dosing characteristics among some subgroups. In particular, higher
doses of landiolol were used in patients with HR 120 beats/min,
patients with respiratory organ infection, and patients without
comorbid septic shock. Two patients received the maximum permit-
ted dose of landiolol at 24 h, and six patients at any time during the
landiolol dosing period.
4. Discussion
The J-Land 3S study showed that the administration of landiolol is
associated with a superior reduction in HR compared with conven-
tional sepsis therapy, and is well tolerated in patients with sepsis-
related tachyarrhythmias [26]. Because patients with sepsis-related
tachyarrhythmias often present with clinically relevant comorbidities
or conditions that may contraindicate or prevent the administration
of other rate-controlling drugs, it is important to evaluate whether
these characteristics may influence the efficacy or safety of landiolol.
Therefore, we investigated the efficacy and safety of landiolol versus
conventional sepsis therapy in patients divided into subgroups
according to baseline characteristics. Overall, we found that landiolol
was effective in the majority of subgroups of patients in terms of
decreasing HR to 6094 beats/min at 24 h, the rate of new-onset
arrhythmia, and 28-day mortality, without marked increases in the
incidence of adverse events. Nevertheless, some findings warrant dis-
cussion.
We found no clear efficacy advantage of landiolol in patients with
a baseline HR of 120 beats/min and in patients with atrial fibrilla-
tion. Regarding baseline HR of 120 beats/min and atrial fibrillation,
one explanation is that prohibited b-blockers were administered as
rescue therapy within 24 h after randomisation to two of the seven
patients in the control group with a HR 120 beats/min and to three
of five patients with atrial fibrillation. This may contribute to a
higher-than-expected rate of achieving the primary endpoint in the
control group.
Another explanation for the lack of clear difference in some
subgroups may relate to the landiolol dosing and caution about
up-titrating the landiolol dose towards the maximum permitted
dose, although the landiolol doses appeared to be greater in
some subgroups of patients, including those who did not achieve
HR control and patients with HR 120 beats/min at randomisa-
tion. The higher doses in the former subgroup may be due to a
lower responsiveness to landiolol in individual patients, some of
whom may have had a HR 120 beats/min at baseline. In some
patients, a low dose may be sufficient to elicit the required HR
lowering effect, but other patients, including those with higher
baseline HR, might require higher landiolol doses to achieve ade-
quate HR control. Because of the potential for excessive reduc-
tions in HR and blood pressure, it is recommended that landiolol
administration is started at a low dose and its dose can be up-
titrated based on the patient’s HR response. However, the maxi-
mum permitted dose of landiolol (20 mg/kg/min) was not reached
in most of the patients, which may indicate some reluctance to
raise the landiolol dose towards the maximum. This may havelimited the potential HR reduction in many patients, especially
those with a high baseline HR. Perhaps counterintuitively, the
dose of landiolol was higher in patients without any adverse
events than in patients who experienced adverse events during
the course of treatment. The reason for this is not clear, but it
suggests that even high doses of landiolol are not necessarily
associated with adverse events.
It is also possible that the clinicians were concerned about exces-
sive reductions in HR with higher doses among patients with atrial
fibrillation, but rescue therapy with another b-blocker was prohib-
ited unless treatment was essential, and these agents were not
administered to any patients in the landiolol group. Nevertheless, the
total landiolol dosing time was about 20 h longer and the maximum
landiolol dose was slightly higher in patients with atrial fibrillation
than in patients with sinus tachycardia. It is possible that the landio-
lol dose was up-titrated more slowly in patients with atrial fibrilla-
tion, resulting in a lower reduction in HR after the 24 h period used
for the primary endpoint.
The hazard ratios for mortality were generally low, in favour of
landiolol, in patients with respiratory infection and in patients with a
SOFA score of <10. Respiratory infections may progress to ARDS [28]
and the mortality risk is higher in patients with ARDS complicated
with new arrhythmia [29]. Landiolol may be associated with a reduc-
tion in new ARDS-associated arrhythmias in patients with respiratory
infections. Meanwhile, it is thought that the pathophysiology of sep-
sis is milder in patients with lower SOFA scores, so the effect of land-
iolol on risk of death may be more apparent in these patients. In a
prior study of esmolol, mortality by 28 days was 494% in the esmolol
group versus 805% in the control group (adjusted hazard ratio 039;
95% CI 026 to 059) [30]. Their results and ours suggest a benefit of
b-blockers on reducing mortality among patients with sepsis-related
tachyarrhythmia. However, we should acknowledge the mortality
rates were quite low in our study, and the results of these subanaly-
ses should be interpreted carefully considering the small numbers of
patients in each subgroup. Therefore, future studies may need to
evaluate the impact of b-blockers on mortality among patients with
sepsis-related tachyarrhythmias.
We also found marked differences in the percentages of patients
with new-onset arrhythmias or adverse events between the landiolol
and control groups among patients with ARDS. New-onset arrhyth-
mia occurred in one of 19 patients in the landiolol group and in five
of 12 patients in the control group, while adverse events occurred in
ten of 19 and 11 of 12 patients, respectively. b-receptor stimulation
has been reported to contribute to the induction of arrhythmia in
ARDS [31]. Thus, we speculate that landiolol attenuated b-receptor
stimulation, without increasing the risk of adverse events in patients
with ARDS. b-blockers are generally contraindicated or administered
with caution in patients with respiratory diseases because of the risk
of bronchospasm [32]. It is interesting to note that esmolol was asso-
ciated with an increase in stroke volume, maintenance of mean arte-
rial pressure, and reduced the norepinephrine requirements in
patients with septic shock [30], and a recent study revealed that
administration of b-blockers improved oxygen saturation without
affecting the mean arterial pressure or an increase in norepinephrine
doses in patients on veno-venous extracorporeal membrane oxygen-
ation [33]. Changes in hemodynamic factors were not assessed in our
study, so future studies may need to evaluate the impact of landiolol
on these factors in patients with septic shock and improve the prog-
nosis of patients with ARDS. Nevertheless, it is reassuring to note that
landiolol was efficacious and did not exacerbate adverse events in
patients with ARDS in the present study.
The population of elderly people is steadily increasing in Japan,
and it is expected that the incidence of sepsis and hence sepsis-
related tachyarrhythmias will increase among older individuals not
only in Japan but also worldwide [3436]. Here, landiolol appeared
to be more effective than conventional sepsis therapy in older
10 N. Matsuda et al. / EClinicalMedicine 28 (2020) 100571patients, without markedly increasing the risk of adverse events.
Thus, the present data suggest that landiolol is also suitable for use in
older patients with sepsis-related tachyarrhythmias.
b-blockers, including landiolol, are generally contraindicated in
patients with cardiogenic shock or acidosis (diabetic and metabolic)
because the negative inotropic effects of b-blockade may exacerbate
cardiac dysfunction in these settings [37]. However, many patients
with sepsis develop septic shock or metabolic/respiratory acidosis.
Shock may result from sepsis-induced myocardial dysfunction or
reduced intravascular volume [27]. The present study included
patients with shock and acidosis, and we observed consistent effi-
cacy and safety of landiolol in patients with or without septic
shock, in patients subdivided by baseline cardiac function (left
ventricular ejection fraction [LVEF] 50% and <50%), and in
patients with or without acidosis. These results suggest that land-
iolol can be used in patients with septic shock and metabolic or
respiratory acidosis, under appropriate monitoring of HR and
blood pressure.
Overall, our present results suggest that landiolol is safe and effec-
tive for treating sepsis-related tachycardia under HR and blood pres-
sure monitoring, regardless of patient characteristics, such as septic
shock, LVEF <50%, acidosis, comorbid acute renal injury, or severe
sepsis.
Similar subanalyses were done in the J-Land study in which
patients with atrial fibrillation or atrial flutter complicated with left
ventricular dysfunction were randomised to landiolol or digoxin [19].
The analyses revealed better efficacy (percentage of patients with HR
<110 beats/min at 2 h after start of intravenous infusion) of landiolol
versus digoxin in a variety of subgroups of patients, including those
with New York Heart Association class III, left ventricular ejection
fraction of 2535% or 3550%, and by chronic kidney disease stage.
Although the results of that study cannot be generalised to the clini-
cal setting of the present study (or vice versa), the results of both
studies suggest that the efficacy of landiolol is essentially unaffected
by key baseline characteristics, and that the efficacy of landiolol may
be more pronounced in certain subgroups of patients who may show
poor responses to conventional therapies.
Some limitations of these analyses warrant mention. In particular,
the overall sample size and numbers of patients in each subgroup
were relatively small due to the study design, which did not require
enrolling minimum numbers of patients in subgroups. Additionally,
we did not perform statistical adjustments for multiplicity of analysis.
These limitations may introduce some bias and should be considered
when interpreting the results. Nevertheless, the subgroup analyses
described here were performed in an exploratory manner and may
support hypothesis-generation, but should not be considered as
hypothesis-confirmatory. In the future, larger studies in certain high-
risk groups of patients with sepsis-related tachyarrhythmias may
help to confirm our findings. However, such studies may be impacted
by a low accrual rate, especially for relatively rare conditions associ-
ated with sepsis/septic shock. In addition, we could not examine the
efficacy or safety of landiolol in some high-risk patients, such as those
with liver injury (e.g. total bilirubin 3 mg/dL), as these patients were
excluded from the J-Land 3S study. Finally, this study was performed
in Japan and enrolled Japanese patients, so the results may not be
generalisable to other populations.
In conclusion, these exploratory results of the J-Land 3S study may
suggest that the efficacy and safety of landiolol for the treatment of
sepsis-related tachyarrhythmia are generally unaffected by most
patient background characteristics. Future studies may provide more
insight into the role of landiolol in this setting and help confirm our
findings.
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